Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Alumis Inc.
Alumis to Present at Leerink's 2025 Global Healthcare Conference
10 mars 2025 08h00 HE
|
Alumis Inc.
Alumis to Present at Leerink's 2025 Global Healthcare Conference
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
08 mars 2025 09h00 HE
|
Alumis Inc.
ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
04 mars 2025 09h01 HE
|
Alumis Inc.
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
28 févr. 2025 09h08 HE
|
Alumis Inc.
Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
27 févr. 2025 16h15 HE
|
Alumis Inc.
Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
10 févr. 2025 16h45 HE
|
Alumis Inc.
Alumis to present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET.
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
06 févr. 2025 16h15 HE
|
Alumis Inc.
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Alumis Strengthens Leadership Team with Key Appointments
28 janv. 2025 08h00 HE
|
Alumis Inc.
Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company.
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
19 déc. 2024 08h00 HE
|
Alumis Inc.
In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
14 nov. 2024 16h05 HE
|
Alumis Inc.
Data at ACR for ESK-001, oral TYK2 inhibitor, demonstrates potential as a high efficacy oral for treatment of Systemic Lupus Erythematosus (SLE).